2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4938 Haploinsufficiency of copy number dosage-sensitive essential genes drives bone marrow failure

Haijiao Zhang, MD, Xuan Luo, MD, PhD2, Daniel Bottomly, MS3, Kangjin Jeong, PhD4, Niveditha Nerlakanti, PhD5, Shannon McWeeney, PhD6, Gordon Mills, MD, PhD7
1 Oregon Health Sciences University, Portland, Oregon, United States
2 Oregon Health Sciences University, Portland, Oregon, United States
3 Oregon Health Sciences University, Portland, Oregon, United States
4 Oregon Health Sciences University, Portland, Oregon, United States
5 Oregon Health Sciences University, Portland, Oregon, United States
6 Oregon Health Sciences University, Portland, Oregon, United States
7 Oregon Health Sciences University, Portland, Oregon, United States

Monosomy 7 is one of the most common cytogenetic abnormalities in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and inherited and acquired bone marrow failure (BMF) disorders, where it is strongly associated with ineffective hematopoiesis, leukemic transformation, treatment resistance, and poor clinical outcomes. Despite its clinical significance, the mechanisms by which chromosome 7 loss drives severe BMF remain poorly understood. Although several putative tumor suppressor genes within the commonly deleted 7q region have been implicated in hematopoietic regulation, hematopoietic phenotypes generally require complete rather than hemizygous loss of these genes, suggesting that deletion of these genes alone cannot explain the profound BMF associated with monosomy 7. Furthermore, genes located outside the minimally deleted 7q region, including those on chromosome 7p, have received comparatively little attention, leaving a major gap in our understanding of why monosomy 7 causes more severe hematopoietic dysfunction and worse clinical outcomes than isolated del(7q). Analogous to the haploinsufficiency of the dosage-sensitive essential genes RPS14 and HSPA9 in del(5q) MDS, we hypothesized that hemizygous deletion of copy number dosage-sensitive essential genes distributed across chromosome 7 impairs core cellular functions required for hematopoietic stem and progenitor cell (HSPC) maintenance, thereby driving BMF.

To systematically identify these genes, we integrated copy number, transcriptomic, proteomic, and genome-wide CRISPR/siRNA dependency datasets from TCGA AML, Beat AML, DepMap, and gnomAD to prioritize chromosome 7 genes that exhibit (i) recurrent hemizygous deletion, (ii) reduced mRNA and/or protein expression following single-copy loss, and (iii) essentiality in genome-wide loss-of-function screens. Candidate genes were subsequently validated using individual CRISPR knockout and competitive growth assays to confirm essentiality. We then generated isogenic single-cell clones carrying either diploid (+/+) or hemizygous (+/−) deletions to establish bona fide haploinsufficient models and verified reduced gene dosage at both the mRNA and protein levels. Using this integrated pipeline, we have so far identified four copy number dosage-sensitive essential genes that exhibit functional haploinsufficiency. To determine their role in hematopoiesis, we disrupted each gene in human cord blood-derived HSPCs using CRISPR/Cas9 and generated hematopoietic-specific conditional knockout mice using the floxed/Vav-iCre system. Hemizygous deletion of each gene significantly reduced colony-forming capacity in colony-forming unit assays and/or caused cytopenias in Vav-iCre–positive, flox/+ mice, demonstrating that partial loss of these essential genes is sufficient to impair hematopoiesis.

In summary, we demonstrate that haploinsufficiency of copy-number dosage-sensitive essential genes compromises core cellular functions, disrupts hematopoiesis, and contributes to BMF.

Haijiao Zhang, MD: turbine.ai - Consultancy (Includes expert testimony)